N1L Is an Ectromelia Virus Virulence Factor and Essential for In Vivo Spread upon Respiratory Infection

ABSTRACT The emergence of zoonotic orthopoxvirus infections and the threat of possible intentional release of pathogenic orthopoxviruses have stimulated renewed interest in understanding orthopoxvirus infections and the resulting diseases. Ectromelia virus (ECTV), the causative agent of mousepox, offers an excellent model system to study an orthopoxvirus infection in its natural host. Here, we investigated the role of the vaccinia virus ortholog N1L in ECTV infection. Respiratory infection of mice with an N1L deletion mutant virus (ECTVΔN1L) demonstrated profound attenuation of the mutant virus, confirming N1 as an orthopoxvirus virulence factor. Upon analysis of virus dissemination in vivo, we observed a striking deficiency of ECTVΔN1L spreading from the lungs to the livers or spleens of infected mice. Investigating the immunological mechanism controlling ECTVΔN1L infection, we found the attenuated phenotype to be unaltered in mice deficient in Toll-like receptor (TLR) or RIG-I-like RNA helicase (RLH) signaling as well as in those missing the type I interferon receptor or lacking B cells. However, in RAG-1−/− mice lacking mature B and T cells, ECTVΔN1L regained virulence, as shown by increasing morbidity and virus spread to the liver and spleen. Moreover, T cell depletion experiments revealed that ECTVΔN1L attenuation was reversed only by removing both CD4+ and CD8+ T cells, so the presence of either cell subset was still sufficient to control the infection. Thus, the orthopoxvirus virulence factor N1 may allow efficient ECTV infection in mice by interfering with host T cell function.

[1]  Barney S. Graham,et al.  Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo , 2010, Proceedings of the National Academy of Sciences.

[2]  M. Alexander-Miller,et al.  Functional Divergence among CD103+ Dendritic Cell Subpopulations following Pulmonary Poxvirus Infection , 2010, Journal of Virology.

[3]  N. Letvin,et al.  Efficient Generation of Mucosal and Systemic Antigen-Specific CD8+ T-Cell Responses following Pulmonary DNA Immunization , 2010, Journal of Virology.

[4]  Mark P. Dodding,et al.  F11-Mediated Inhibition of RhoA Signalling Enhances the Spread of Vaccinia Virus In Vitro and In Vivo in an Intranasal Mouse Model of Infection , 2009, PloS one.

[5]  H. Meyer,et al.  Zoonotic poxviruses , 2009, Veterinary microbiology.

[6]  Daniel R. Caffrey,et al.  AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC , 2009, Nature.

[7]  Geoffrey L. Smith,et al.  Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection , 2008, The Journal of general virology.

[8]  S. Green,et al.  Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus , 2008, PloS one.

[9]  S. Akira,et al.  Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. , 2008, The Journal of clinical investigation.

[10]  Hideo Negishi,et al.  Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules , 2008, Proceedings of the National Academy of Sciences.

[11]  L. Lanier,et al.  A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease , 2008, PLoS pathogens.

[12]  S. Jonjić,et al.  Immune evasion of natural killer cells by viruses. , 2008, Current opinion in immunology.

[13]  S. Akira,et al.  Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses , 2007, Journal of Virology.

[14]  S. Locarnini,et al.  Toll‐like receptors, RIG‐I‐like RNA helicases and the antiviral innate immune response , 2007, Immunology and cell biology.

[15]  K. Honda,et al.  DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response , 2007, Nature.

[16]  D. Stuart,et al.  Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein , 2007, The Journal of general virology.

[17]  J. Corbett,et al.  Induction of Natural Killer Cell Responses by Ectromelia Virus Controls Infection , 2007, Journal of Virology.

[18]  G. McFadden,et al.  Immunopathogenesis of poxvirus infections: forecasting the impending storm , 2007, Immunology and cell biology.

[19]  R. Liddington,et al.  Vaccinia virus N1L protein resembles a B cell lymphoma‐2 (Bcl‐2) family protein , 2006, Protein science : a publication of the Protein Society.

[20]  C. Coban,et al.  Essential role of IPS-1 in innate immune responses against RNA viruses , 2006, The Journal of experimental medicine.

[21]  D. Gridley,et al.  Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor , 2006, The journal of gene medicine.

[22]  G. Karupiah,et al.  Obligatory Requirement for Antibody in Recovery from a Primary Poxvirus Infection , 2006, Journal of Virology.

[23]  G. Karupiah,et al.  Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function , 2006, Journal of Virology.

[24]  B. Finlay,et al.  Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral Pathogens , 2006, Cell.

[25]  R. Buller,et al.  Ectromelia virus: the causative agent of mousepox. , 2005, The Journal of general virology.

[26]  A. Bowie,et al.  Poxvirus Protein N1L Targets the I-κB Kinase Complex, Inhibits Signaling to NF-κB by the Tumor Necrosis Factor Superfamily of Receptors, and Inhibits NF-κB and IRF3 Signaling by Toll-like Receptors* , 2004, Journal of Biological Chemistry.

[27]  Fatema A. Legrand,et al.  Induction of Potent Humoral and Cell-Mediated Immune Responses by Attenuated Vaccinia Virus Vectors with Deleted Serpin Genes , 2004, Journal of Virology.

[28]  P. Eckburg,et al.  Human monkeypox: an emerging zoonosis , 2004, The Lancet. Infectious diseases.

[29]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[30]  A. Meyers,et al.  Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[32]  G. McFadden,et al.  Poxvirus Immunomodulatory Strategies: Current Perspectives , 2003, Journal of Virology.

[33]  C. Staib,et al.  Improved host range selection for recombinant modified vaccinia virus Ankara. , 2003, BioTechniques.

[34]  Susana Guerra,et al.  Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L , 2002, Oncogene.

[35]  D. Tscharke,et al.  The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. , 2002, The Journal of general virology.

[36]  D A Henderson,et al.  Diagnosis and management of smallpox. , 2002, The New England journal of medicine.

[37]  L. Lefrançois,et al.  Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.

[38]  D. Smee,et al.  Treatment of Lethal Vaccinia Virus Respiratory Infections in Mice with Cidofovir , 2001, Antiviral chemistry & chemotherapy.

[39]  A. Alcamí,et al.  Expression of Secreted Cytokine and Chemokine Inhibitors by Ectromelia Virus , 2000, Journal of Virology.

[40]  A. Bowie,et al.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Upton,et al.  Ectromelia virus virulence factor p28 acts upstream of caspase-3 in response to UV light-induced apoptosis. , 2000, The Journal of general virology.

[42]  L. Morrison,et al.  A Poxvirus Protein That Binds to and Inactivates IL-18, and Inhibits NK Cell Response1 , 2000, The Journal of Immunology.

[43]  M. Bray,et al.  A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. , 2000, Archives of pathology & laboratory medicine.

[44]  C. Upton,et al.  Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox. , 2000, Virus research.

[45]  J. Panus,et al.  A third distinct tumor necrosis factor receptor of orthopoxviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Karupiah,et al.  Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection , 1996, Journal of virology.

[47]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.

[48]  R. Moyer,et al.  The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of Balb/c mice. , 1993, Virology.

[49]  G. Karupiah,et al.  Importance of interferons in recovery from mousepox , 1993, Journal of virology.

[50]  K. Rajewsky,et al.  Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting , 1993, Cell.

[51]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[52]  P. Marrack,et al.  Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. , 1990, Science.

[53]  B. Moss,et al.  Transient dominant selection of recombinant vaccinia viruses , 1990, Journal of virology.

[54]  R. Jaenisch,et al.  β2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells , 1990, Nature.

[55]  B. Moss,et al.  Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. , 1989, Virology.

[56]  S. Ho,et al.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.

[57]  B. Coupar,et al.  A dominant selectable marker for the construction of recombinant poxviruses. , 1988, Gene.

[58]  C. A. Phillips,et al.  Vaccinia pneumonia in mice. A light and electron microscopic and viral assay study. , 1966, The American journal of pathology.

[59]  F. Fenner,et al.  Mouse-pox; infectious ectromelia of mice; a review. , 1949, Journal of immunology.

[60]  F. Fenner The clinical features and pathogenesis of mouse‐pox (infectious ectromelia of mice) , 1948 .

[61]  J. Löwer,et al.  Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. , 2009, The Journal of infectious diseases.

[62]  G. Häcker,et al.  Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis , 2008, Cell Death and Differentiation.

[63]  D. Brownstein,et al.  Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus , 2005, Archives of Virology.

[64]  G. McFadden Poxvirus tropism , 2005, Nature Reviews Microbiology.

[65]  P. Kellam,et al.  Poxvirus genomes: a phylogenetic analysis. , 2004, The Journal of general virology.

[66]  G. Kotwal,et al.  Growing poxviruses and determining virus titer. , 2004, Methods in molecular biology.

[67]  M. Lorenzo,et al.  Construction and isolation of recombinant vaccinia virus using genetic markers. , 2004, Methods in molecular biology.

[68]  Antonio Alcami,et al.  Viral mimicry of cytokines, chemokines and their receptors , 2003, Nature Reviews Immunology.

[69]  D. Smee,et al.  Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. , 2000, The Journal of infectious diseases.

[70]  Geoffrey L. Smith,et al.  Vaccinia virus immune evasion. , 1999, Immunology letters.

[71]  E. Koonin,et al.  A poxvirus protein with a RING zinc finger motif is of crucial importance for virulence. , 1994, Virology.

[72]  F. Fenner Smallpox and its eradication , 1988 .